↓ Skip to main content

Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?

Overview of attention for article published in Orphanet Journal of Rare Diseases, January 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?
Published in
Orphanet Journal of Rare Diseases, January 2015
DOI 10.1186/s13023-014-0222-5
Pubmed ID
Authors

Emanuela Palmerini, Maria Benassi, Irene Quattrini, Laura Pazzaglia, Davide Donati, Stefania Benini, Gabriella Gamberi, Marco Gambarotti, Piero Picci, Stefano Ferrari

Abstract

BackgroundSynovial sarcoma (SS) is a rare tumor, with dismal survival when metastatic. The role of adjuvant chemotherapy is debated. New prognostic and predictive factors are needed.MethodsWe reviewed patients with localized SS; SS18-SSX fusion transcript presence was confirmed by FISH and RT-PCR. Expression of CXCR4, IGF-1R and Ezrin were evaluated by immunohistochemistry.ResultsTumor samples from 88 SS patients (45 female; 43 male) with median age 37 years (range 11¿63) were selected. The size of the lesion was¿>¿5 cm in 68% of patients and 34% of cases presented biphasic histotype. All patients underwent surgery, 56% adjuvant radiotherapy (RT), 65% adjuvant chemotherapy. A positive stain for IGF-1R was detected in 55 patients, with nucleus expression in 21 patients. CXCR4 was expressed in 74 patients, nuclear pattern in 31 patients. 80 SS were positive to Ezrin, 48 had cytoplasmatic location, 32 membrane location. With a median follow-up of 6 years (1¿30 years), the 5-year overall survival (OS) was 70% (95%CI 60¿81). 5-year OS was 63% (95%CI 41-85%) for patients with positive IGF-1R/nuclear expression, and 73% (95%CI 61-85%; P¿=¿0.05) in negative patients. 5-year OS was 47% (95%CI 27-66%) in patients with positive CXCR4/nuclear staining, and 86% (95%CI 76-96%, P =0.0003) in negative cases. No survival difference was found according to Ezrin expression. By multivariate analysis, nuclear expression of CXCR4 and IGF-1R was confirmed independent adverse prognostic factor for SS patient survival linked to the use of chemotherapy.ConclusionsOur findings have important potential implications demonstrating that together with clinical prognostic factors such as radiotherapy and age, CXCR4 and IGF-1R negatively influences survival in patients with localized SS. We believe that further studies addressed to the effects of CXCR4 and IGF-1R inhibitors on cell viability and function are needed to plan new and more appropriate SS treatments.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 28%
Student > Ph. D. Student 5 20%
Other 2 8%
Student > Doctoral Student 2 8%
Student > Bachelor 2 8%
Other 3 12%
Unknown 4 16%
Readers by discipline Count As %
Medicine and Dentistry 11 44%
Biochemistry, Genetics and Molecular Biology 4 16%
Agricultural and Biological Sciences 3 12%
Veterinary Science and Veterinary Medicine 1 4%
Chemistry 1 4%
Other 1 4%
Unknown 4 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2015.
All research outputs
#3,288,135
of 4,773,711 outputs
Outputs from Orphanet Journal of Rare Diseases
#639
of 803 outputs
Outputs of similar age
#110,552
of 160,401 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#27
of 45 outputs
Altmetric has tracked 4,773,711 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 803 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,401 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.